摘要: … their promise of productivity. Although many industry analysts seem to think that this productivity challenge is a new problem, it is in fact rather old: output-based productivity has been in …
nature.com
sci-hub.se 参考文章(14)
Richard C. Edmunds, Craig P. Tanio, Philip C. Ma, Splicing a Cost Squeeze into the Genomics Revolution The McKinsey Quarterly. pp. 15- ,(2001)
Walter Sneader, Drug prototypes and their exploitation ,(1996)
Bruce Booth, Rodney Zemmel, Quest for the best Nature Reviews Drug Discovery. ,vol. 2, pp. 838- 841 ,(2003) , 10.1038/NRD1203
Philip Ma, Rodney Zemmel, Value of novelty Nature Reviews Drug Discovery. ,vol. 1, pp. 571- 572 ,(2002) , 10.1038/NRD884
David F Horrobin, Innovation in the pharmaceutical industry. Journal of the Royal Society of Medicine. ,vol. 93, pp. 341- 345 ,(2000) , 10.1177/014107680009300702
Michal Vieth, Miles G. Siegel, Richard E. Higgs, Ian A. Watson, Daniel H. Robertson, Kenneth A. Savin, Gregory L. Durst, Philip A. Hipskind, Characteristic physical properties and structural fragments of marketed oral drugs. Journal of Medicinal Chemistry. ,vol. 47, pp. 224- 232 ,(2004) , 10.1021/JM030267J
Mark C. Wenlock, Rupert P. Austin, Patrick Barton, Andrew M. Davis, Paul D. Leeson, A comparison of physiochemical property profiles of development and marketed oral drugs. Journal of Medicinal Chemistry. ,vol. 46, pp. 1250- 1256 ,(2003) , 10.1021/JM021053P
J. Langrish, Innovation in pharmaceuticals Research Policy. ,vol. 1, pp. 88- 98 ,(1971) , 10.1016/0048-7333(71)90008-4
Andrew L. Hopkins, Colin R. Groom, The druggable genome Nature Reviews Drug Discovery. ,vol. 1, pp. 727- 730 ,(2002) , 10.1038/NRD892
David F. Horrobin, Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nature Reviews Drug Discovery. ,vol. 2, pp. 151- 154 ,(2003) , 10.1038/NRD1012